1211 related articles for article (PubMed ID: 25687024)
1. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
4. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
Isaac M; Mireskandari K; Tehrani N
J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041
[TBL] [Abstract][Full Text] [Related]
5. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
6. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
7. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
Kuo HK; Sun IT; Chung MY; Chen YH
Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
[TBL] [Abstract][Full Text] [Related]
9. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.
Mueller B; Salchow DJ; Waffenschmidt E; Joussen AM; Schmalisch G; Czernik C; Bührer C; Schunk KU; Girschick HJ; Winterhalter S
Br J Ophthalmol; 2017 Mar; 101(3):365-370. PubMed ID: 27301450
[TBL] [Abstract][Full Text] [Related]
10. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan.
Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN
Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
12. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
13. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
14. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
15. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
16. Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP.
Anand N; Blair MP; Greenwald MJ; Rodriguez SH
J AAPOS; 2019 Apr; 23(2):88.e1-88.e6. PubMed ID: 30797978
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity.
Ekinci DY; Çelik K
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042
[TBL] [Abstract][Full Text] [Related]
19. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
